Shares of CollaGenex Pharmaceuticals Inc. fell Wednesday after the company shut down development for its rosacea treatment incyclinide, after the drug candidate failed to reduce inflammatory lesions compared with placebo in a midstage study.
From: biz.yahoo.com
CollaGenex Shares Fall on Rosacea Study
Posted by Ruslan Abuzant at 2:09 PM
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment